Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for Prevention of Thrombocytopenia in Cancer Patients
NCT00037791Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 1999
- Modality
- Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of recombinant human thrombopoietin in Thrombocytopenia (3 arms), sponsored by Pfizer. Primary endpoint: Proportion of patients requiring platelet transfusion. Started Dec 1999; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00037791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037791.